November 3, 2025 — Leads & Copy — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will participate in investor conferences, including the 2025 Stifel Healthcare Conference on November 11 and the J.P. Morgan U.S. Opportunities Forum 2025 on November 12.
Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. Mirum’s late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum has also initiated a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.
Source: Mirum Pharmaceuticals, Inc.
